The Relationship Between Omentin-1 Levels and Disease Severity in Pregnant Women Diagnosed with Preeclampsia

Read full text Summarise with VIRAT
Authors: Hacer ÖZDEMİR, Uğurcan Zorlu, Gizem Durmaz, Tayfur Çift
Cited by: 0
References: 1

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: The aim of this study is to compare serum Omentin-1 levels in pregnant women diagnosed with preeclampsia with those in normal pregnancies, and to investigate the role of this molecule in the pathogenesis of the condition.Materials and Methods: This study included voluntary pregnant women who applied to the Gynecology and Obstetrics Clinic of Bursa Higher Specialization Training and Research Hospital, University of Health Sciences, between June 2018 and September 2018. The study group consisted of 90 pregnant women diagnosed with preeclampsia, while the control group included 90 pregnant women with no complications during follow-up. The groups were compared in terms of Omentin-1 levels.Findings: A total of 180 pregnant women, aged between 18 and 40, were evaluated. The mean age was 28.35 ± 6.13 years (29.13 ± 6.25 in the patient group and 27.58 ± 6.02 in the control group). The mean Omentin-1 level was 63.10 Ng/mL in the preeclampsia group and 64.85 Ng/mL in the control group. There were no significant differences in Omentin-1 levels between the groups (p>0.005).Conclusion: When comparing the serum Omentin-1 levels of the 90 pregnant women diagnosed with preeclampsia to those of the 90 normal pregnant women, no statistically significant differences were observed between the groups (p>0.005).

Fields of Study & Subjects

Pregnancy and preeclampsia studies Neurological Complications and Syndromes Pregnancy-related medical research

Publication details

Journal / source
Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
Volume
23
Issue
1
Pages
34–40
Publication date
31 March 2026
Language
TR